| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-143 |
DRI_Challenge |
denotes |
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. |
| T2 |
144-305 |
DRI_Background |
denotes |
Importance: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. |
| T3 |
306-401 |
DRI_Outcome |
denotes |
Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated. |
| T4 |
402-568 |
DRI_Background |
denotes |
Objective: To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died. |
| T5 |
569-775 |
DRI_Background |
denotes |
Design, Setting, and Participants: Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. |
| T6 |
776-826 |
DRI_Approach |
denotes |
The final date of follow-up was February 13, 2020. |
| T7 |
868-930 |
DRI_Outcome |
denotes |
Main Outcomes and Measures: The development of ARDS and death. |
| T8 |
931-1056 |
DRI_Background |
denotes |
Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed. |
| T9 |
1057-1181 |
DRI_Background |
denotes |
Results: Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. |
| T10 |
1182-1269 |
DRI_Background |
denotes |
Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. |
| T11 |
1270-1763 |
DRI_Outcome |
denotes |
In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). |
| T12 |
2333-2345 |
DRI_Background |
denotes |
High fever ( |
| T13 |
2351-2501 |
DRI_Background |
denotes |
) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). |
| T14 |
2502-2620 |
DRI_Background |
denotes |
Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72). |
| T15 |
2621-2770 |
DRI_Background |
denotes |
Conclusions and Relevance: Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. |
| T16 |
2771-2905 |
DRI_Challenge |
denotes |
Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. |
| T17 |
2906-2998 |
DRI_Background |
denotes |
Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS. |
